UNMC_Acronym_Vert_sm_4c
University of Nebraska Medical Center

Authorized COVID Antiviral Fails to Cut Hospitalization Risk

MedPageToday – Molnupiravir failed to reduce the risk for hospitalization or death in high-risk COVID-19 outpatients who took the oral antiviral within 5 days of symptoms, a large open-label multicenter trial found. In more than 25,000 participants in the PANORAMIC study, the rate of all-cause hospitalization or death at 28 days was an identical 0.8% whether individuals were randomized to molnupiravir or usual care (adjusted OR 1.06, 95% bayesian credible interval [BCI] 0.80-1.40), reported Christopher Butler, MD, of the University of Oxford in England, and co-authors.

Leave a comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.